Browsing publications by Dr Ian Hardcastle

Newcastle AuthorsTitleYearFull text
Dr Catherine Drummond
Arman Esfandiari
Dr Xiaohong Lu
Dr Claire Hutton
Dr Jennifer Jackson
et al.
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation2016
Dr Gary Beale
Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
Stephanie Myers
Dr Ruth Bawn
Betty Cottyn
Dr Lauren Molyneux
Dr Celine Cano
et al.
High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors2016
Tristan Reuillon
Duncan Miller
Stephanie Myers
Dr Lauren Molyneux
Dr Celine Cano
et al.
Pyrrolcarboxamide Derivatives for the Inhibition of ERK52016
Dr Ian Hardcastle
Aryne generation vs. Truce-Smiles and fries rearrangements during the Kobayashi fragmentation reaction: a new bi-aryl synthesis2015
Dr Andrey Zaytsev
Dr Barry Dodd
Professor Bernard Golding
Professor Roger Griffin
Dr Xiaohong Lu
et al.
Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach2015
Bian Zhang
Professor Bernard Golding
Dr Ian Hardcastle
Small-molecule MDM2-p53 inhibitors: recent advances2015
Dr Benoit Carbain
Dr Allyson Campbell
Dr Celine Cano
Professor Jane Endicott
Professor Bernard Golding
et al.
8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode2014
Alex Liu
Dr Catherine Drummond
Professor Jane Endicott
Professor Bernard Golding
Professor Roger Griffin
et al.
An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones2014
Dr Ruth Bawn
Tristan Reuillon
Professor Bernard Golding
Professor Roger Griffin
Dr Ian Hardcastle
et al.
Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy2014
12345678910